Skip to main content
Erschienen in: Annals of Hematology 10/2020

25.05.2020 | Letter to the Editor

Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia

verfasst von: Amanda Tey, Bianca Mohan, Ron Cheah, Claire Dendle, Gareth Gregory

Erschienen in: Annals of Hematology | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Heath CH, Slavin MA, Sorrell TC, Handke R, Harun A, Phillips M, Nguyen Q, Delhaes L, Ellis D, Meyer W, Chen SCA (2009) Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 15(7):689–693CrossRef Heath CH, Slavin MA, Sorrell TC, Handke R, Harun A, Phillips M, Nguyen Q, Delhaes L, Ellis D, Meyer W, Chen SCA (2009) Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 15(7):689–693CrossRef
2.
Zurück zum Zitat Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt L, Ito JI, Kauffman CA, Lyon GM, Marr KA, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wingard JR, Walsh TJ, Kontoyiannis DP (2011) Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 17(10):1855–1864CrossRef Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt L, Ito JI, Kauffman CA, Lyon GM, Marr KA, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wingard JR, Walsh TJ, Kontoyiannis DP (2011) Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 17(10):1855–1864CrossRef
3.
Zurück zum Zitat Cooley L, Spelman D, Thursky K, Slavin M (2007) Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis 13(8):1170–1177CrossRef Cooley L, Spelman D, Thursky K, Slavin M (2007) Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis 13(8):1170–1177CrossRef
4.
Zurück zum Zitat Rodriguez-Tudela JL, Berenguer J, Guarro J, Kantarcioglu AS, Horre R, de Hoog GS et al (2009) Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 47(4):359–370 Rodriguez-Tudela JL, Berenguer J, Guarro J, Kantarcioglu AS, Horre R, de Hoog GS et al (2009) Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 47(4):359–370
5.
Zurück zum Zitat Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997–1007CrossRef Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997–1007CrossRef
6.
Zurück zum Zitat Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, Fernández-Ruiz M, Grossi P, Aguado JM (2018) ESCMID study Group for Infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect 24:S53–S70CrossRef Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, Fernández-Ruiz M, Grossi P, Aguado JM (2018) ESCMID study Group for Infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect 24:S53–S70CrossRef
7.
Zurück zum Zitat Cheah CY, Fowler NH (2016) Idelalisib in the management of lymphoma. Blood 128(3):331–336CrossRef Cheah CY, Fowler NH (2016) Idelalisib in the management of lymphoma. Blood 128(3):331–336CrossRef
8.
Zurück zum Zitat Hilal T, Gea-Banacloche JC, Leis JF (2018) Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: linking mechanisms with infections. Blood Rev 32(5):387–399CrossRef Hilal T, Gea-Banacloche JC, Leis JF (2018) Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: linking mechanisms with infections. Blood Rev 32(5):387–399CrossRef
9.
Zurück zum Zitat Husain S, Muñoz P, Forrest G, Alexander BD, Somani J, Brennan K et al (2005) Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 40(1):89–99CrossRef Husain S, Muñoz P, Forrest G, Alexander BD, Somani J, Brennan K et al (2005) Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 40(1):89–99CrossRef
Metadaten
Titel
Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia
verfasst von
Amanda Tey
Bianca Mohan
Ron Cheah
Claire Dendle
Gareth Gregory
Publikationsdatum
25.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 10/2020
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-04087-2

Weitere Artikel der Ausgabe 10/2020

Annals of Hematology 10/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.